INS and polycystic ovary syndrome: This leads to an inevitable therapeutic increase in the dose of insulin therapy, resulting in exogenous systemic hyperinsulinemia, which stimulates androgen over-synthesis and secretion in the ovaries and adrenal glands, which in turn may lead to the development of PCOS [16].